AbbVie stock gained 1.11 percent before October 30 results

Published on 10/04/2026 at 09:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock reached USD 262.82 at the October 2 close after quarterly revenue hit USD 16.99 billion. Scotiabank kept a USD 280 target on October 1, while Q3 results are due October 30.

Flatlay-Produktfoto mit generischen Blisterpackungen, Ampullen, Pipette und abstraktem Wertpapierschein — AbbVie Inc. US00287Y1091 Flatlay generische Blisterpackungen Ampullen Pipette Aktien Zertifikat und ISIN Karte, Illustration mit AI erstellt.

AbbVie Inc. stock (ISIN US00287Y1091) closed at USD 262.82 on the NYSE on October 2, 2026, gaining 1.11 percent and ending 2.44 percent below its 52-week high of USD 269.39. The move came as the company entered the final weeks before its next quarterly report and continued to build its post-Humira growth story.

Juvmo adds a new growth angle

According to MarketBeat on October 2, 2026, FDA approval of Juvmo for Parkinson's disease supported the stock narrative, with a commercial launch targeted for October 2026. The treatment gives AbbVie another neuroscience asset alongside its established immunology and specialty-care portfolio.

The same report highlighted continued RINVOQ data in vitiligo through week 76. For investors, the important distinction is timing: Juvmo and RINVOQ represent future product contributions, while the latest revenue figures show the business already operating at a larger scale.

Revenue beat sets the benchmark

AbbVie's second-quarter 2026 revenue reached USD 16.99 billion, up 10.2 percent from USD 15.42 billion in the same quarter of 2025, according to Markets Insider. Adjusted EPS was USD 3.65, ahead of the USD 3.61 consensus cited by MarketBeat.

That combination gives the October report a clear benchmark: investors will compare the next quarter's sales and adjusted EPS with the USD 16.99 billion and USD 3.65 recorded for Q2 2026. The key operating question is whether newer medicines can offset pressure from older products.

Analyst target stays above the stock

Scotiabank analyst Louise Chen maintained a Buy rating and set a USD 280 price target on October 1, 2026, as reported by Markets Insider. That target lies 6.5 percent above the October 2 closing price, leaving the analyst view dependent on continued execution rather than a single product launch.

October 30 is the next test

AbbVie will announce third-quarter 2026 results before the market opens on October 30, 2026, according to Yahoo Finance. The report will put the USD 3.65 adjusted EPS benchmark, the pipeline narrative and the valuation premium to a fresh test.